References in periodicals archive ?
This was reportedly due to the commercialisation of Beleodaq in the US by Onxeo's partner Spectrum Pharmaceuticals.
The main growth catalysts are expected to be Livatag, Beleodaq and AsiDNATM,
Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL).
Beleodaq works by stopping enzymes that contribute to T-cells, a type of immune cell, becoming cancerous.
The safety and effectiveness of Beleodaq was evaluated in a clinical study involving 129 participants with relapsed or refractory PTCL.
Beleodaq also received orphan product designation by the FDA because it is intended to treat a rare disease or condition.
M2 PHARMA-February 10, 2014-Spectrum Pharmaceuticals'new drug application for Beleodaq accepted for filing by US Food and Drug Administration
US-based Spectrum Pharmaceuticals' new drug application for Beleodaq has been accepted for filing by the US Food and Drug Administration, it was reported on Friday.
M2 EQUITYBITES-February 10, 2014-Spectrum Pharmaceuticals'new drug application for Beleodaq accepted for filing by US Food and Drug Administration